Vaccine Assumptions HPV-16 HPV-18 HPV-31, 33, 45, 52, and 58
Cervical cancer
Malea 0.411 0.411 0.411
Female 0.76 0.76 0.76
Protection against cervical HPV infections becoming persistent 0.988 0.988 0.988
Protection against HPV-related CIN 0.97 0.97 0.97
Vaginal and vulvar cancers
Malea 0.411 0.621 0.621
Female 0.76 0.963 0.963
Protection against vaginal/vulvar HPV infections becoming persistent 0.988 0.984 0.984
Protection against HPV-related /VaIN/VIN 1 1 1
Anal cancers
Male 0.762 1 0.762
Female 0.762 1 0.762
Protection against anal HPV infections becoming persistent
Male 0.938 0.999 0.938
Female 0.938 0.999 0.938
Protection against HPV-related AIN 0.655 1 0.655
H&N cancers
Male 0.411 0.621 0.621
Female 0.760 0.963 0.963
Protection against H&N infections becoming persistent
Male 0.787 0.96 0.96
Female 0.988 0.984 0.984
Protection against HPV-related H&N neoplasia 0 0 0
Penile cancer
Male 0.411 0.621 0.621
Femaleb 0.760 0.963 0.963
Protection against penile HPV-16/18 infections becoming persistent
Protection against HPV-related PIN 0.787 0.960 0.960
Vaccine efficacy against HPV-6/11 infection HPV-6 HPV-11
Females 0.761 0.761
Males 0.49 0.57
Protection against HPV-6/11–related genital warts
Females 0.989 1
Males 0.843 0.909
Protection against HPV-6/11–related CIN1 1 1